Clinical trial shows omalizumab (Xolair) treats multiple severe food allergies more effectively than oral immunotherapy, with ...

Omalizumab (Xolair) injections outperformed oral immunotherapy (OIT) in increasing tolerance among children with multi-food ...

Omalizumab was found to be more effective than multi-allergen oral immunotherapy (OIT) in reducing allergic reactions in patients with 1 or more food allergies, according to results from Stage 2 of ...

The high rate of allergic reactions and other intolerable side effects of oral immunotherapy in the NIH-funded trial ...

In the trials, omalizumab and multi-allergen oral immunotherapy showed alike efficacy in protecting against food allergies, ...

The high rate of side effects from oral immunotherapy in the NIH trial explains the superiority of omalizumab. A clinical ...

Roche's Xolair outperformed oral immunotherapy in a Phase 3 trial for food allergies, showing better tolerance and fewer ...

Patients with multiple food allergies introduced allergens into their diets after using omalizumab, researchers reported at ...

In a new study, omalizumab, an injectable drug for food allergies, performed better than oral immunotherapy. A subsequent ...

Roche’s asthma drug Xolair appears to be safer and more effective than oral immunotherapy at treating adults and children ...

Additionally, preliminary results from Stage 3 of the OUtMATCH study provide early data on introducing allergenic foods into a patient’s diet after stopping Xolair. These findings were featured as ...

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively ...